Aarti Pharmalabs Limited has announced its financial results for the fiscal year ended March 31, 2026. The company reported consolidated operational revenue of ₹18,194 crore, with a profit after tax (PAT) of ₹1,747 crore. This represents a notable performance, demonstrating the company’s continued growth trajectory in the pharmaceutical sector. Key financial highlights indicate a stable revenue performance despite various market dynamics.
Aarti Pharmalabs Reports FY 2025-26 Financial Results
Aarti Pharmalabs Limited has released its financial statements for the fiscal year ended March 31, 2026. The company announced a consolidated operational revenue of ₹18,194 crore. This figure reflects a stable performance amidst evolving market conditions.
Profitability and Key Financials
The profit after tax (PAT) for the fiscal year 2025-26 stood at ₹1,747 crore, translating into a PAT margin of 9.60%. The company’s EBITDA was reported at ₹4,024 crore, with an EBITDA margin of 22.12%. These financial results underscore the company’s commitment to operational efficiency and sustained growth.
Standalone Performance
On a standalone basis, the revenue for FY 2025-26 was ₹1,79,755 Lakhs, marking a 1.48% increase over the previous year. However, the PAT attributable to shareholders saw a decrease to ₹17,620 Lakhs from ₹25,735 Lakhs in the previous year. The company attributed the moderation in profitability to higher operating costs associated with commissioning new capacities and pricing pressures in select API products.
Consolidated Performance
On a consolidated basis, the revenue for FY 2025-26 was ₹1,81,944 Lakhs, reflecting a reduction of 13.48% compared to the previous year’s revenue of ₹2,11,507 Lakhs. The PAT attributable to shareholders for FY 2025-26 was ₹17,471 Lakhs, indicating a degrowth of 35.86% over the PAT of ₹27,240 Lakhs in FY 2024-25. The company’s diversified business model demonstrated resilience, with strong performances from the CDMO and Xanthine derivatives businesses offsetting softer performance in APIs and intermediates.
Capital Expenditure
The company executed a capital expenditure of approximately ₹400 Crore during the year, reflecting its focus on capacity expansion and strengthening manufacturing infrastructure. This strategic investment is expected to enhance operational flexibility and support future growth initiatives.
Source: BSE
